Analysts see $3B potential in Sanofi-Regeneron cholesterol drug alirocumab

09/26/2013 | Reuters

Sanofi and Regeneron Pharmaceuticals' late-stage cholesterol therapy candidate alirocumab has the potential to become a blockbuster with more than $3 billion in sales, analysts said. Alirocumab belongs to a class of drugs called PCSK9 inhibitors. Deutsche Bank analysts said peak annual sales of alirocumab could reach exceed $3 billion, and BioMedTracker, an independent research firm, predicted sales of $3.7 billion by 2023.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA